A ReD alum discusses how her fieldwork at ReD prepared her for her current role at a genomics company.

In this groundbreaking study of cancer patients treated with immunotherapy for stage IV cancer, ReD has illuminated the particular state of patients who survive longer than their initial prognosis. These patients are able to achieve a state of normalcy, despite having a terminal condition.

More life sciences companies should build their R&D on the unmet needs of patients in real world contexts.

In business thinking, ‘core competencies’ have long been seen as the critical factor that distinguishes great from good. Great companies have strong core competencies that they constantly leverage and develop. On the other hand, companies who do not understand their own strengths and weaknesses cannot execute at the highest proficiency.